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Psoriasis is a common inflammatory condition involving the skin, scalp, nails and joints. 
It significantly increases the risk of cardiovascular events and death in those affected, 
above Framingham Risk Score (FRS) prediction alone
1
. There is a dose-response 
element; those with the most severe psoriasis (assessed by the psoriasis area severity 
index (PASI) score) are at the greatest risk. A UK study estimated the excess risk as 
being equivalent to having a diagnosis of diabetes
2
. Psoriasis often becomes apparent at a 
young age, exposing patients to higher risk for several decades. This translates into a 
lifetime excess of cardiovascular mortality of approximately 2
3
. 
 
Psoriasis and atherosclerosis share many pathological pathways. These include T-helper 
cell activation, an excess of Th-1 cytokines and imbalances in the interleukin 1 pathway 
favoring inflammation
4
. As well as driving atherothrombosis, there is evidence that 
psoriasis patients have an excess of both aortic valve stenosis and arterial stiffening, both 
conditions believed to have inflammatory bases
5,6
.  
 
In this edition of ATVB, Naik and colleagues (Naik et al), measured vascular 
inflammation in a group of 60 subjects with mild to moderate psoriasis and compared 
their findings to control subjects. They hypothesised that the extent of vascular 
inflammation, quantified with FDG PET imaging, would be related to the severity of 
psoriasis, estimated by the PASI score. They also gathered evidence in support of their 
belief that the well-recognised links between psoriasis and vascular disease might be 
mediated by inflammation via neutrophils. The recruits were relatively young, although 
they had suffered psoriasis for a median of 20 years. Many were already receiving 
systemic psoriasis therapy at the time of PET imaging. Overall, the group was classified 
as low-risk according to FRS. Their findings were instructive. First, FDG uptake was 
greater in psoriasis patients than controls, with TBR values suggestive of at least 
moderate arterial inflammation
7
. Psoriasis severity was significantly positively associated 
with vascular inflammation, even after adjusting for FRS and CRP levels. Supportive of 
their second hypothesis, psoriasis patients had significantly higher levels of neutrophil-
associated cytokines than control subjects, and in particular, S100A8/A9 (an endogenous 
TLR4 activator protein binding complex) was related to both psoriasis severity and 
arterial inflammation. 
 
FDG PET has been used to measure vascular inflammation in many inflammatory 
conditions, including rheumatoid disease (where it also demonstrated that systemic 
therapy lowered vascular inflammation)
8
, chronic obstructive pulmonary disease
9
 and, 
most widely atherosclerosis, where it highlighted the beneficial effects of statin therapy 
on the vessel wall
10
 and can predict clinical events
11
. Because FDG accumulation and 
retention within the vessel wall reflects glucose usage, many cell types located there can 
influence the final signal. In the hypoxic atherosclerotic plaque micro-environment, 
macrophages predominate
12
, particularly once activated
13
. In psoriasis, the cell type 
responsible for vascular FDG uptake is unknown.  
 
Does systemic psoriasis therapy influence surrogate markers of cardiovascular risk? In a 
small study that recruited patients with severe psoriasis and measured carotid and 
brachial arterial intima-media thickness (IMT), therapy with etanercept, infliximab or 
adalimumab did result in significant regression of IMT measurements, but this was 
restricted to those without established atherosclerosis at baseline
14
. Bissonnette and 
colleagues
15
, used vascular FDG PET as a marker of inflammation, but failed to meet 
their primary endpoint in a larger, randomised study with the potent anti-inflammatory 
drug adalimumab. Interestingly, a retrospective study by Prodanovich et al. showed that 
patients with psoriasis treated with methotrexate had decreased rates of vascular disease 
when compared to controls
16
. It will be instructive to see whether the same holds true in 
the Cardiovascular Inflammation Reduction Trial that will randomly allocate 7,000 
patients with prior myocardial infarction and either type 2 diabetes or the metabolic 
syndrome to low-dose methotrexate or placebo over an average follow-up period of 3 to 5 
years
17
.  
  
Summary 
 
This work extends the use of imaging to uncover potentially important links between two, 
on the face of it, very different conditions. It seems plausible, that, as the authors suggest, 
smouldering skin lesions produce inflammatory cytokines that can trigger remote 
inflammation. This has recently been reported
18
, albeit in reverse, after myocardial 
infarction, where global inflammation is up-regulated after an acute coronary syndrome 
putting patients at high risk of recurrent events
19
. Naik et al’s study was cross-sectional, 
and, as acknowledged by the authors, their hypotheses need to be confirmed or refuted by 
ongoing longitudinal studies to prove cause and effect. 
 
In terms of psoriasis management, their study elegantly illustrates the paradox of 
significant vascular inflammation yet low Framingham scores and provides an 
explanation for it via neutrophil-mediated inflammation. Whether psoriasis patients 
should undergo testing for subclinical atherosclerosis
20
 or receive aggressive statin 
therapy is not known, but the case is strengthened by this paper. By providing 
mechanistic insights between psoriasis and atherosclerotic inflammation, this study 
suggests new therapeutic targets that could be exploited to lower the excessive 
cardiovascular disease burden that these patients experience. 
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